Raymond James downgraded Haemonetics (HAE) to Outperform from Strong Buy with a price target of $78, down from $105. The firm also removed the shares from its Analyst Current Favorite list. Haemonetics’ interventional technologies franchise declined in Q2 due to issues around selling execution, the analyst tells investors in a research note. Raymond James views the issues as fixable, but its confidence on the execution and timing of doing so has waned. The firm continues to view Haemonetics as an attractive and undervalued asset.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HAE: